Skip to main content

Medtronic Value Stock - Dividend - Research Selection

Medtronic

ISIN: IE00BTN1Y115 , WKN: A14M2J

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Medtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company\'s Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment offers surgical care, wound closure, electrosurgical, hernia mechanical device, mesh implant, ablation, interventional lung, ventilator, capnography, airway, sensor, monitor, compression, dialysis, enteral feeding, wound care, and medical surgical products; stapling, vessel sealing, fixation, and hardware instruments; and gastrointestinal, temperature management, inhalation therapy, and renal care solutions.

 

The company\'s Restorative Therapies Group segment offers products for spine, bone graft substitutes, biologic products, trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis, as well as products to treat conditions of the ear, nose, and throat; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The company\'s Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and Web-based therapy management software.

 

The company was founded in 1949 and is headquartered in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Medtronic: Undervalued Dividend Aristocrat With High Margins

2024-10-10
Medtronic is a compelling investment with its diverse revenue streams, strong growth, and promising product pipeline at an attractive value. See more on MDT here.

Cosmo Pharmaceuticals NV (CMOPF) (H1 2024) Earnings Call Highlights: Revenue Surge and ...

2024-10-09
Cosmo Pharmaceuticals NV (CMOPF) reports a remarkable revenue increase and strengthens its position with strategic alliances and innovative advancements.

MDT Stock Trades Near 52-Week High: Is it a Smart Buy Now?

2024-10-09
The latest rate cut should help Medtronic expand in the AFib, structural heart, robotics, neuromodulation, hypertension and diabetes markets.

Buy 4 October Dividend Aristocrats & Watch 10

2024-10-09
67 Aristocrats, screened as of October 7, 2024 represented all eleven Morningstar Sectors. Explore more details here.

Medtronic price target raised to $98 from $92 at RBC Capital

2024-10-09
RBC Capital raised the firm’s price target on Medtronic to $98 from $92 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q3 results. The firm’s industry checks suggest that Q3 underlying utilization trends were positive despite typical summer seasonality driving a sequential step-down in elective procedures, the analyst tells investors in a research note. Investor sentiment is also positive for MedTech stocks going into the earnings season, and invest

The Zacks Analyst Blog JPMorgan, Medtronic, Shopify and Perma-Pipe International

2024-10-09
JPMorgan, Medtronic, Shopify and Perma-Pipe International are included in this Analyst Blog.

Top Research Reports for JPMorgan Chase, Medtronic & Shopify

2024-10-08
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Medtronic plc (MDT) and Shopify Inc. (SHOP), as well as a micro-cap stock Perma-Pipe International Holdings, Inc. (PPIH).

Medtronic : launches the Avalus Ultra™ valve in Western Europe at the European Association for Cardio-Thoracic Surgery (EACTS) Congress

2024-10-08
Medtronic plc, a global leader in healthcare technology, today announced the launch of the Avalus Ultra™ Bioprosthesis valve in Western Europe during the EACTS annual congress in Lisbon. The Avalus...

ClearBridge Value Strategy Q3 2024 Commentary

2024-10-08
The Strategy underperformed its benchmark during a volatile quarter, as detractors in the financials and industrials sectors overcame positive contributions from our utilities holdings.

Returns On Capital At Medtronic (NYSE:MDT) Have Stalled

2024-10-08
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...